NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Treeline Biosciences

Treeline Biosciences

Private
Watertown, MassachusettsHealthcare & Life Scienceshttps://treeline.bio/

Last Round

Reverse Merger

Jun 8, 2026

Est. Valuation

$2.96B

Total Funding Raised

$2B

Momentum

Top 5%

of companies Caplight tracks

Company Overview

Treeline Biosciences is a biotechnology company that develops transformative precision medicines for cancer and other serious conditions through a drug discovery platform integrating mechanistic biology, medicinal chemistry, computational science, and structural biology.

Sector

Healthcare & Life Sciences

Verticals

Drug Discovery, Biotechnology, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Application

Keywords

small-molecule therapeuticsdrug discoveryoncologycomputational chemistrystructural biologyclinical-stage biopharmabiotechin silico drug discoveryAI-driven drug discoveryprecision medicineclinical trialsdrug pipelinepharma R&Dsmall-molecule drugs

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Treeline Biosciences Comparables

Compare Treeline Biosciences with similar companies based on industry and business-model similarity.

Treeline Biosciences comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Odyssey Therapeutics
88%
Xaira Therapeutics
85%
Valo Health
84%

Treeline Biosciences Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Reverse MergerJun 8, 2026
Series ASep 3, 2025
Series AOct 17, 2024
Series AOct 17, 2022
Series AApr 9, 2021

Key People

Founding team and executive leadership

Josh Bilenker

CEO And Co-Founder

Founding Team

Spencer Smith

Chief Financial Officer

Executive Team

Treeline Biosciences Investors

Notable investors and investment history

Treeline Biosciences investors
InvestorRounds
Andreessen HorowitzSeries A
Soleus CapitalSeries A
Access IndustriesSeries A
Kohlberg Kravis RobertsSeries A
Boxer CapitalSeries A
GVSeries A
Ajax HealthSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 18, 2026

    Monthly visitors increased 59% MoM.

  • Jun 8, 2026

    Raised $2.5B in an M&A round.

Treeline Biosciences Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Treeline Biosciences Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Treeline Biosciences's valuation, stock price, and market status.

Firmographic Details

HeadquartersWatertown, Massachusetts
Employee Range172
Year Founded2021
Last FundingJun 8, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.